{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06251310",
            "orgStudyIdInfo": {
                "id": "TEAD-AST-101"
            },
            "organization": {
                "fullName": "SpringWorks Therapeutics, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "SW-682 in Advanced Solid Tumors",
            "officialTitle": "A Phase 1a/1b Dose Escalation, Dose Expansion Study of SW-682 in Participants With Advanced Solid Tumors Enriched for Those With Hippo Pathway Mutations",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "sw-in-advanced-solid-tumors"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-07",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2030-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2030-06",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-02-01",
            "studyFirstSubmitQcDate": "2024-02-01",
            "studyFirstPostDateStruct": {
                "date": "2024-02-09",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-18",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-21",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "SpringWorks Therapeutics, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a first-in-human (FIH), Phase 1a/1b open-label, multicenter, dose escalation and dose expansion study of SW-682 in adult participants with metastatic or unresectable advanced solid tumors with or without Hippo pathway alterations that are refractory to, or have progressed, during or after appropriate prior systemic anticancer therapy, including chemotherapy, immunotherapy, radiation therapy or targeted therapy, or for which no treatment is available, or prior standard of care (SOC) therapy was not tolerated and for which there is no further SOC treatment available. The study includes a Part 1 (Phase 1a) dose escalation phase and a Part 2 (Phase 1b) dose expansion to optimize the dose to be used for further development. All participants will self-administer SW-682 by mouth in 28-day cycles."
        },
        "conditionsModule": {
            "conditions": [
                "Advanced Solid Tumor",
                "Mesothelioma, Malignant"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "interventionModelDescription": "The study will be conducted in two sequential parts: Part 1 dose escalation and Part 2 dose expansion.",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 186,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Phase 1 Dose Escalation Cohorts Ranging in Dose",
                    "type": "EXPERIMENTAL",
                    "description": "Participants with advanced solid tumors with or without Hippo pathway mutations will receive SW-682 tablets administered orally in continuous 28-day cycles. SW-682 dosage and frequency of administration will vary by cohort.",
                    "interventionNames": [
                        "Drug: SW-682"
                    ]
                },
                {
                    "label": "Part 2 Dose Expansion Cohort 1",
                    "type": "EXPERIMENTAL",
                    "description": "Participants with mesothelioma with or without NF2 mutations will receive SW-682 tablets administered orally in continuous 28-day cycles at the recommended dose for expansion, based on Part 1 data.",
                    "interventionNames": [
                        "Drug: SW-682"
                    ]
                },
                {
                    "label": "Part 2 Dose Expansion Cohort 2",
                    "type": "EXPERIMENTAL",
                    "description": "Participants with advanced solid tumors with NF2 mutations will receive SW-682 tablets administered orally in continuous 28-day cycles at the recommended dose for expansion, based on Part 1 data.",
                    "interventionNames": [
                        "Drug: SW-682"
                    ]
                },
                {
                    "label": "Part 2 Dose Expansion Cohort 3",
                    "type": "EXPERIMENTAL",
                    "description": "Participants with advanced solid tumors with other Hippo pathway mutations identified during Part 1 (Phase 1a) dose escalation will receive SW-682 tablets administered orally in continuous 28-day cycles at the recommended dose for expansion, based on Part 1 data.",
                    "interventionNames": [
                        "Drug: SW-682"
                    ]
                },
                {
                    "label": "Part 2 Dose Expansion Cohort 4",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive SW-682 tablets administered orally in continuous 28-day cycles at the recommended dose for expansion, based on Part 1 data, with appropriate combination therapy, identified based on Part 1 data.",
                    "interventionNames": [
                        "Drug: SW-682",
                        "Drug: Combination Therapy"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "SW-682",
                    "description": "SW-682 tablet administered orally",
                    "armGroupLabels": [
                        "Part 2 Dose Expansion Cohort 1",
                        "Part 2 Dose Expansion Cohort 2",
                        "Part 2 Dose Expansion Cohort 3",
                        "Part 2 Dose Expansion Cohort 4",
                        "Phase 1 Dose Escalation Cohorts Ranging in Dose"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Combination Therapy",
                    "description": "Appropriate combination therapy",
                    "armGroupLabels": [
                        "Part 2 Dose Expansion Cohort 4"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Incidence of Adverse Events (Part 1 Only)",
                    "description": "Safety and tolerability endpoint evaluation via incidence of dose limiting toxicities (DLTs), serious adverse events (SAEs), treatment emergent adverse events (TEAE)",
                    "timeFrame": "Up to 24 months"
                },
                {
                    "measure": "Maximum Tolerated Dose (Part 1 Only)",
                    "description": "The maximum tolerated dose (MTD) for SW-682, if any, will be based on safety and tolerability during the first 28 days of treatment in Cycle 1.",
                    "timeFrame": "Up to 24 months"
                },
                {
                    "measure": "Recommended Dose for Expansion (Part 1 Only)",
                    "description": "The recommended dose for expansion (RDE) will be determined based on all safety, tolerability, pharmacokinetics (PK), preliminary antitumor efficacy, and other available data from Part 1 of the study.",
                    "timeFrame": "Up to 24 months"
                },
                {
                    "measure": "Objective Response Rate (Part 2 Only)",
                    "description": "Objective response rate (ORR), defined as the proportion of participants with confirmed CR or PR using RECIST v1.1, mRECIST for mesothelioma, and/or GCIG CA-125 for ovarian cancer, as applicable, assessed by the investigator.",
                    "timeFrame": "Up to 24 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Change in plasma and urine concentrations of SW-682",
                    "description": "Plasma and urine concentrations of SW-682 and any relevant metabolite(s) will be measured to evaluate systemic exposures and renal elimination.",
                    "timeFrame": "Up to 24 months"
                },
                {
                    "measure": "Objective Response Rate (Part 1 Only)",
                    "description": "Objective response rate (ORR), defined as the proportion of participants with confirmed CR or PR using RECIST v1.1, mRECIST for mesothelioma, and/or GCIG CA-125 for ovarian cancer, as applicable, assessed by the investigator.",
                    "timeFrame": "Up to 24 months"
                },
                {
                    "measure": "Disease Control Rate",
                    "description": "Disease control rate (DCR), defined as the percentage of participants with CR, PR, or stable disease (SD) after starting study treatment.",
                    "timeFrame": "Up to 24 months"
                },
                {
                    "measure": "Duration of Response",
                    "description": "Duration of response (DoR), defined as the time from response (CR + PR using RECIST v1.1, mRECIST and/or (GCIG) criteria for CA-125 response in ovarian cancer, as applicable) to disease progression and/or death, whichever occurs first.",
                    "timeFrame": "Up to 24 months"
                },
                {
                    "measure": "Progression-Free Survival",
                    "description": "Progression-free survival (PFS), defined as the time from the date of the first administration of study treatment to the first documented disease progression per RECIST v1.1, mRECIST, and/or GCIG CA-125, as applicable, or death due to any cause, whichever occurs first.",
                    "timeFrame": "Up to 24 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Key Inclusion Criteria:\n\n* Histologically confirmed, metastatic, or unresectable solid cancer that has either not responded to or progressed during or after appropriate prior systemic anticancer therapy including chemotherapy, immunotherapy, radiation therapy, or appropriate targeted therapy, or for which there is no treatment available or prior SOC therapy was not tolerated and for which there is no further SOC treatment available\n* Part 1: must have one of the following:\n\n  * Mesothelioma with or without NF2 mutations\n  * Advanced solid tumors with NF2 mutations\n  * Advanced solid tumors with other Hippo pathway mutations or fusions (e.g., FAT1, LATS1/2, YAP fusions; WWTR1-CAMTA1 in EHE).\n* Part 2: must have the tumor histology and oncogenic mutation or genomic aberration specific to each dose expansion cohort defined below:\n\n  * Cohort 1: Participants with mesothelioma with or without NF2 mutations\n  * Cohort 2: Participants with advanced solid tumors with NF2 mutations\n  * Cohort 3: Participants with advanced solid tumors with other Hippo pathway mutations identified during Part 1 (Phase 1a) dose escalation\n  * Cohort 4: SW-682 with appropriate combination therapy.\n* In both parts, participants should have known oncogenic mutation identified by Next Generation Sequencing or local assay\n* Must have archival tumor tissue or agree to a fresh tumor biopsy at screening\n* Measurable disease per RECIST 1.1\n* Eastern Cooperative Oncology Group (ECOG) performance status of \u22641\n* Adequate bone marrow, kidney, hepatic, and coagulation function\n\nKey Exclusion Criteria:\n\n* Evidence of symptomatic CNS metastases, leptomeningeal carcinomatosis, or untreated spinal cord compression\n* Clinically significant cardiac disease or abnormal cardiac parameters\n* Preexistence or inheritance of a familial renal syndrome\n* Concomitant non-anti-arrhythmic medications that are known to prolong the QTc interval\n* Concomitant medicines that are known strong/moderate inhibitors or inducers of cytochrome P450 3A4 (CYP3A4) and/or CYP1A2 within 14 days or 5 half-lives before the first dose of study treatment\n* Concomitant medicines that are known sensitive substrates of CYP3A4, CYP2C19, CYP2D6, CYP1A2, and/or CYP2B6 within 14 days or 5 half-lives before the first dose of study treatment\n* Concomitant medicines that are known sensitive substrates of PGP, BCRP, OATP1B1, OATP1B3, OAT1, OAT3, MATE1, MATE2-K, OCT2\n* Clinically significant active infection (bacterial, fungal, or viral)",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "SpringWorks Clinical",
                    "role": "CONTACT",
                    "phone": "877-279-4870",
                    "email": "clinical@springworkstx.com"
                }
            ],
            "locations": [
                {
                    "facility": "SpringWorks Clinical Trial Site",
                    "status": "ACTIVE_NOT_RECRUITING",
                    "city": "Scottsdale",
                    "state": "Arizona",
                    "zip": "85251",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.50921,
                        "lon": -111.89903
                    }
                },
                {
                    "facility": "SpringWorks Clinical Trial Site",
                    "status": "ACTIVE_NOT_RECRUITING",
                    "city": "La Jolla",
                    "state": "California",
                    "zip": "92037",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 32.84727,
                        "lon": -117.2742
                    }
                },
                {
                    "facility": "SpringWorks Clinical Trial Site",
                    "status": "ACTIVE_NOT_RECRUITING",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90033",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                },
                {
                    "facility": "SpringWorks Clinical Trial Site",
                    "status": "ACTIVE_NOT_RECRUITING",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90095",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                },
                {
                    "facility": "SpringWorks Clinical Trial Site",
                    "status": "ACTIVE_NOT_RECRUITING",
                    "city": "Tampa",
                    "state": "Florida",
                    "zip": "33612",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 27.94752,
                        "lon": -82.45843
                    }
                },
                {
                    "facility": "SpringWorks Clinical Trial Site",
                    "status": "ACTIVE_NOT_RECRUITING",
                    "city": "Cleveland",
                    "state": "Ohio",
                    "zip": "44106",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.4995,
                        "lon": -81.69541
                    }
                },
                {
                    "facility": "SpringWorks Clinical Trial Site",
                    "status": "ACTIVE_NOT_RECRUITING",
                    "city": "Portland",
                    "state": "Oregon",
                    "zip": "97239",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 45.52345,
                        "lon": -122.67621
                    }
                },
                {
                    "facility": "Mary Crowley Cancer Research",
                    "status": "RECRUITING",
                    "city": "Dallas",
                    "state": "Texas",
                    "zip": "75230",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Douglas Orr, MD",
                            "role": "CONTACT",
                            "phone": "972-566-3000",
                            "email": "referral@marycrowley.org"
                        },
                        {
                            "name": "Douglas Orr, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.78306,
                        "lon": -96.80667
                    }
                },
                {
                    "facility": "SpringWorks Clinical Trial Site",
                    "status": "ACTIVE_NOT_RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008654",
                    "term": "Mesothelioma"
                },
                {
                    "id": "D000086002",
                    "term": "Mesothelioma, Malignant"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000000236",
                    "term": "Adenoma"
                },
                {
                    "id": "D000009375",
                    "term": "Neoplasms, Glandular and Epithelial"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000018301",
                    "term": "Neoplasms, Mesothelial"
                },
                {
                    "id": "D000008175",
                    "term": "Lung Neoplasms"
                },
                {
                    "id": "D000012142",
                    "term": "Respiratory Tract Neoplasms"
                },
                {
                    "id": "D000013899",
                    "term": "Thoracic Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000010997",
                    "term": "Pleural Neoplasms"
                },
                {
                    "id": "D000008171",
                    "term": "Lung Diseases"
                },
                {
                    "id": "D000012140",
                    "term": "Respiratory Tract Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M11634",
                    "name": "Mesothelioma",
                    "asFound": "Mesothelioma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M2537",
                    "name": "Mesothelioma, Malignant",
                    "asFound": "Mesothelioma, Malignant",
                    "relevance": "HIGH"
                },
                {
                    "id": "M3591",
                    "name": "Adenoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M12320",
                    "name": "Neoplasms, Glandular and Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M20445",
                    "name": "Neoplasms, Mesothelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M11172",
                    "name": "Lung Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M14979",
                    "name": "Respiratory Tract Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M16658",
                    "name": "Thoracic Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M13887",
                    "name": "Pleural Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M11168",
                    "name": "Lung Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14977",
                    "name": "Respiratory Tract Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T3584",
                    "name": "Malignant Mesothelioma",
                    "asFound": "Mesothelioma, Malignant",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}